Artificial transcription factor that contains a zinc Finger Protein polidactilica aimed specifically at a receptor gene Promoter FUSED to a Protein Domain inhibitor or Activator, a nuclear localization sequence and a transduction Domain q； Pharmaceutical composition The EU understands； and its use.
The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically a receptor gene promoter fused to an inhibitory or activatory protein domain, a nuclear localization sequence, and a protein transduction domain. In particular examples these receptor gene promoters regulate the expression of the endothelin receptor A, the endothelin receptor B, the Toll-like receptor 4 or the high-affinity IgE receptor. Artificial transcription factors directed to the endothelin A or B receptors are useful in the treatment of diseases modulated by endothelin, such as cardiovascular diseases, and, in particular, eye diseases, e.g. retinal vein occlusion, retinal artery occlusion, macular edema, optic neuropathy, central serous chorioretinopathy, retinitis pigmentosa, Leber's hereditary optic neuropathy, and the like. Artificial transcription factors directed to the Toll-like receptor 4 or the IgE receptor are useful for the treatment of autoimmune disorders, and the like, and allergic disorders, respectively.FACTOR DE TRANSCRIPCION ARTIFICIAL QUE COMPRENDE UNA PROTEINA DE DEDO DE ZINC POLIDACTILICA DIRIGIDA ESPECIFICAMENTE A UN PROMOTOR DE GEN RECEPTOR FUSIONADO A UN DOMINIO DE PROTEINA INHIBIDOR O ACTIVADOR, UNA SECUENCIA DE LOCALIZACION NUCLEAR Y UN DOMINIO DE TRANSDUCCION； COMPOSICION FARMACEUTICA QUE LO COMPRENDE； Y SU USO.
